Anthem Biosciences, an India-based CDMO, submitted a filing (PDF) at the end of 2024 to announce its plans for a 33.95 ...

India's pharmaceutical industry is poised for a dramatic transformation by 2025, driven by AI, machine learning, and ...

The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...

Big pharma has grown wary of investing in the area, and is increasingly looking for new risk-sharing approaches. GSK recently licensed-out one of its own molecules, SB742457, to small biotech firm ...

The rise of A.I. in the pharmaceutical industry has placed unprecedented power in the hands of tech-driven drug discovery, raising questions about innovation, control and patient safety.